Cargando…

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study

COVID‐19 continues to be a relevant issue among patients with haematological malignancies (HM). Vaccines are frequently not effective in subjects on active treatment. In this multicentre retrospective study of Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), we collected data from 91...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marasco, Vincenzo, Piciocchi, Alfonso, Candoni, Anna, Pagano, Livio, Guidetti, Anna, Musto, Pellegrino, Bruna, Riccardo, Bocchia, Monica, Visentin, Andrea, Turrini, Mauro, Tucci, Alessandra, Pilerci, Sofia, Fianchi, Luana, Salvini, Marco, Galimberti, Sara, Coviello, Elisa, Selleri, Carmine, Luppi, Mario, Crea, Enrico, Fazi, Paola, Passamonti, Francesco, Corradini, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Covid‐19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796521/ https://www.ncbi.nlm.nih.gov/pubmed/35906881 http://dx.doi.org/10.1111/bjh.18385

Ejemplares similares

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
por: Breccia, Massimo, et al.
Publicado: (2020)

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

EHMTI-0321. Restricted diffusion in painful ophthalmoplegia
por: Choi, JH, et al.
Publicado: (2014)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
por: Palandri, Francesca, et al.
Publicado: (2020)

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
por: Breccia, M., et al.
Publicado: (2022)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Aplicaciones informáticas de hojas de cálculo UF0321 /
por: Sánchez Estella, Óscar
Publicado: (2021)

Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey
por: Valentini, Caterina Giovanna, et al.
Publicado: (2021)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

PA03.21. To evaluate the effect of Vaman, Kanak Bindu Aristha & Kusthakalanal Taila on Psoriasis
por: Hada, Saurabh Singh, et al.
Publicado: (2013)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study
por: Efficace, Fabio, et al.
Publicado: (2021)

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
por: Chiaretti, Sabina, et al.
Publicado: (2021)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
por: Corradini, Paolo, et al.
Publicado: (2020)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
por: Innocenti, Idanna, et al.
Publicado: (2022)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
por: Specchia, Giorgina, et al.
Publicado: (2021)

Noninvasive prenatal testing detected acute myeloid leukemia in paucisymptomatic pregnant patient
por: Rengifo, Laura Yissel, et al.
Publicado: (2020)

ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia
por: Rivellese, Felice, et al.
Publicado: (2020)

SARS-CoV-2 Delta VOC in a Paucisymptomatic Dog, Italy
por: Pascucci, Ilaria, et al.
Publicado: (2022)

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022)

Immune Response Failure in Paucisymptomatic Long-Standing SARS-CoV-2 Spreaders
por: Corrao, Salvatore, et al.
Publicado: (2021)

Several cases of arterial thrombosis of the limbs revealing asymptomatic and paucisymptomatic COVID-19 infection
por: Niang, Ibrahima, et al.
Publicado: (2021)

Persistent Increase of Sympathetic Activity in Post-Acute COVID-19 of Paucisymptomatic Healthcare Workers
por: Liviero, Filippo, et al.
Publicado: (2023)

Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications
por: Martelli, Eugenio, et al.
Publicado: (2023)

Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA
por: Efficace, Fabio, et al.
Publicado: (2023)

Paucisymptomatic pulmonary and right ear tuberculosis in young woman suffering from anorexia and bulimia nervosa
por: Garaci, Francesco Giuseppe, et al.
Publicado: (2019)

Viral Ribonucleic Acid Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Coronavirus Disease 2019 Patients
por: Samaddar, Arghadip, et al.
Publicado: (2020)

Paucisymptomatic Tetralogy of Fallot diagnosed in a 56-year-old patient: a case report
por: Hakim, Kaouthar, et al.
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection
por: De Biasi, Sara, et al.
Publicado: (2021)

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
por: Visco, Carlo, et al.
Publicado: (2022)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials
por: Ramadan, Safaa M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a7b2pip000s4v4h8hkqonotsao